on-interventional, prospective, multicenter study to evaluate treatment satisfaction, treatment preference, quality of life, and tolerability under treatment with Briumvi® for relapsing forms of multiple sclerosis (RMS) with active disease in daily clinical practice
Recruiting
- Conditions
- G35Multiple sclerosis
- Registration Number
- DRKS00034406
- Lead Sponsor
- euraxpharm Pharmaceuticals, S.L.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Established clinical diagnosis of RMS with active disease.
- Having been prescribed treatment with Briumvi® according to label and treatment is already initiated, with enrollment occurring no more than 90 days after the first dose.
OR:
Patient with newly prescribed Briumvi® in accordance with the label and about to start treatment with Briumvi® at Visit 1.
- Ability to understand the purpose and risks of the study and willing to provide signed and dated study-specific ICF.
Exclusion Criteria
Patient cannot be regularly followed up for organizational or geographic reasons.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method